The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today. Dimethyl ...

WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...

The FINANCIAL — Biogen unveiled new TECFIDERA (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients ...

The FINANCIAL — Biogen on April 20 announced new data that continue to support TECFIDERA (dimethyl fumarate) as an effective, long-term treatment for people who are living with relapsing forms of ...

FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...

Tecfidera (dimethyl fumarate) is a prescription drug used to treat multiple sclerosis (MS). Tecfidera’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

Generic Tecfidera is a treatment for patients with relapsing forms of multiple sclerosis, while generic Vimpat is used as monotherapy or adjunctive therapy in patients with partial onset seizures.